Marketdash
Back to Stock Market News

5 Stocks That Captured Investor Attention as Markets Dipped Monday

MarketDash Editorial Team
3 hours ago
While major indexes slipped on Monday, several stocks made dramatic moves that caught traders' eyes. From a biotech's 42% plunge after disappointing trial results to a tech firm's 109% surge on an AI deal, here's what had investors talking.

Monday wasn't exactly a banner day for the broader market. The Dow Jones Industrial Average dropped 0.5% to close at 48,461.93, while the S&P 500 shed 0.35% to finish at 6,905.74. The Nasdaq fell 0.5% to 23,474.34. But beneath that sleepy surface, several individual stocks were putting on quite a show.

Here's what retail traders and investors were buzzing about throughout the session.

Brand Engagement Network: AI Deal Sends Shares Soaring

Brand Engagement Network Inc. (BNAI) had the kind of day every penny stock dreams about, rocketing 108.75% to close at $2.50. The stock hit an intraday high of $2.91 and a low of $1.77, trading within its 52-week range of $11.80 to $1.18. After hours, reality set in a bit as shares retreated nearly 7% to $2.33.

The catalyst? Brand Engagement Network announced it secured a Vendor Services Project Agreement with a major global advertising agency. The deal involves building a custom AI engagement solution for a top-10 pharmaceutical company's prescription drug. The company expects to recognize revenue from the project in the fourth quarter of 2025, which explains some of the enthusiasm even if the cash won't hit the books for a while.

Ultragenyx Pharmaceutical: Trial Results Disappoint

Ultragenyx Pharmaceutical Inc. (RARE) had the opposite kind of day, with shares plummeting 42.32% to close at $19.72. The stock bounced between a high of $20.49 and a low of $18.41, with that low marking the bottom of its 52-week range. The stock edged up 1.17% to $19.95 in after-hours trading, but that's cold comfort after losing nearly half your value in a single session.

The culprit was Phase 3 trial data for setrusumab (UX143), a treatment for osteogenesis imperfecta that Ultragenyx is developing with partner Mereo BioPharma. The genetic bone disorder involves collagen mutations that lead to brittle bones and frequent fractures, so an effective treatment would address a real medical need. Unfortunately, the Orbit and Cosmic trial results weren't what investors were hoping to see.

Cemtrex: Turnaround Complete, Eyes on Growth

Cemtrex Inc. (CETX) shares fell 7.46% during regular trading to end at $2.11, moving between an intraday high of $2.23 and low of $2.10. But the after-hours session told a different story, with the stock popping 42.65% to $3.01 as investors digested the company's full-year results.

Cemtrex reported fiscal 2025 revenue of $76.5 million, up from $66.9 million the prior year, and returned to operating profitability with operating income of $0.5 million compared to a $5.3 million loss in fiscal 2024. Both business segments showed growth, with Security revenue climbing 20% to $38.4 million and Industrial Services increasing 9% to $38 million. Gross profit improved to $32.3 million, representing 42% of revenue.

The balance sheet got some love too. After year-end, the company reduced debt by approximately $7.8 million and improved liquidity by roughly $9 million. Management said it has two acquisitions in the works and characterized fiscal 2025 as the culmination of its turnaround efforts, setting the stage for additional operating leverage and growth in 2026.

Sidus Space: Capital Raise and Defense Contract Fuel Rally

Sidus Space Inc. (SIDU) jumped 32.90% to close at $2.56, reaching a high of $2.73 and a low of $2.20 within its 52-week range of $6.75 to $0.63. The momentum continued after hours, with shares gaining another 11.1% to $2.85.

Sidus Space announced it was preparing to close a public offering expected to raise approximately $16.2 million in gross proceeds through the sale of 10.8 million Class A shares priced at $1.50 each. The company plans to use the funds for working capital and general corporate purposes, including manufacturing expansion and product development to scale operations.

The stock also got a boost from Sidus Space's recent selection as a contract awardee under the Missile Defense Agency's SHIELD IDIQ program, which supports the U.S. "Golden Dome" missile defense initiative. Getting on a government contract vehicle like that can open doors to significant future revenue.

Tesla: Safety Investigation Weighs on Shares

Tesla Inc. (TSLA) shares declined 3.27% to finish at $459.64, with an intraday high of $469.40 and low of $459. The 52-week range runs from $498.82 down to $214.25.

The decline came after U.S. auto safety regulators opened a new defect investigation into the 2022 Model 3 over concerns about the emergency door release. The probe covers approximately 179,000 vehicles and follows a petition alleging the mechanical release was hidden, unlabeled, and not intuitive to use, particularly for rear-seat passengers. That's the kind of safety concern that tends to weigh on automaker stocks, even if it ultimately doesn't result in a formal recall.

According to market data, Tesla stock currently has a Value ranking in the 3rd percentile compared to other EV players in its peer group.

Back to Stock Market News

5 Stocks That Captured Investor Attention as Markets Dipped Monday

MarketDash Editorial Team
3 hours ago
While major indexes slipped on Monday, several stocks made dramatic moves that caught traders' eyes. From a biotech's 42% plunge after disappointing trial results to a tech firm's 109% surge on an AI deal, here's what had investors talking.

Monday wasn't exactly a banner day for the broader market. The Dow Jones Industrial Average dropped 0.5% to close at 48,461.93, while the S&P 500 shed 0.35% to finish at 6,905.74. The Nasdaq fell 0.5% to 23,474.34. But beneath that sleepy surface, several individual stocks were putting on quite a show.

Here's what retail traders and investors were buzzing about throughout the session.

Brand Engagement Network: AI Deal Sends Shares Soaring

Brand Engagement Network Inc. (BNAI) had the kind of day every penny stock dreams about, rocketing 108.75% to close at $2.50. The stock hit an intraday high of $2.91 and a low of $1.77, trading within its 52-week range of $11.80 to $1.18. After hours, reality set in a bit as shares retreated nearly 7% to $2.33.

The catalyst? Brand Engagement Network announced it secured a Vendor Services Project Agreement with a major global advertising agency. The deal involves building a custom AI engagement solution for a top-10 pharmaceutical company's prescription drug. The company expects to recognize revenue from the project in the fourth quarter of 2025, which explains some of the enthusiasm even if the cash won't hit the books for a while.

Ultragenyx Pharmaceutical: Trial Results Disappoint

Ultragenyx Pharmaceutical Inc. (RARE) had the opposite kind of day, with shares plummeting 42.32% to close at $19.72. The stock bounced between a high of $20.49 and a low of $18.41, with that low marking the bottom of its 52-week range. The stock edged up 1.17% to $19.95 in after-hours trading, but that's cold comfort after losing nearly half your value in a single session.

The culprit was Phase 3 trial data for setrusumab (UX143), a treatment for osteogenesis imperfecta that Ultragenyx is developing with partner Mereo BioPharma. The genetic bone disorder involves collagen mutations that lead to brittle bones and frequent fractures, so an effective treatment would address a real medical need. Unfortunately, the Orbit and Cosmic trial results weren't what investors were hoping to see.

Cemtrex: Turnaround Complete, Eyes on Growth

Cemtrex Inc. (CETX) shares fell 7.46% during regular trading to end at $2.11, moving between an intraday high of $2.23 and low of $2.10. But the after-hours session told a different story, with the stock popping 42.65% to $3.01 as investors digested the company's full-year results.

Cemtrex reported fiscal 2025 revenue of $76.5 million, up from $66.9 million the prior year, and returned to operating profitability with operating income of $0.5 million compared to a $5.3 million loss in fiscal 2024. Both business segments showed growth, with Security revenue climbing 20% to $38.4 million and Industrial Services increasing 9% to $38 million. Gross profit improved to $32.3 million, representing 42% of revenue.

The balance sheet got some love too. After year-end, the company reduced debt by approximately $7.8 million and improved liquidity by roughly $9 million. Management said it has two acquisitions in the works and characterized fiscal 2025 as the culmination of its turnaround efforts, setting the stage for additional operating leverage and growth in 2026.

Sidus Space: Capital Raise and Defense Contract Fuel Rally

Sidus Space Inc. (SIDU) jumped 32.90% to close at $2.56, reaching a high of $2.73 and a low of $2.20 within its 52-week range of $6.75 to $0.63. The momentum continued after hours, with shares gaining another 11.1% to $2.85.

Sidus Space announced it was preparing to close a public offering expected to raise approximately $16.2 million in gross proceeds through the sale of 10.8 million Class A shares priced at $1.50 each. The company plans to use the funds for working capital and general corporate purposes, including manufacturing expansion and product development to scale operations.

The stock also got a boost from Sidus Space's recent selection as a contract awardee under the Missile Defense Agency's SHIELD IDIQ program, which supports the U.S. "Golden Dome" missile defense initiative. Getting on a government contract vehicle like that can open doors to significant future revenue.

Tesla: Safety Investigation Weighs on Shares

Tesla Inc. (TSLA) shares declined 3.27% to finish at $459.64, with an intraday high of $469.40 and low of $459. The 52-week range runs from $498.82 down to $214.25.

The decline came after U.S. auto safety regulators opened a new defect investigation into the 2022 Model 3 over concerns about the emergency door release. The probe covers approximately 179,000 vehicles and follows a petition alleging the mechanical release was hidden, unlabeled, and not intuitive to use, particularly for rear-seat passengers. That's the kind of safety concern that tends to weigh on automaker stocks, even if it ultimately doesn't result in a formal recall.

According to market data, Tesla stock currently has a Value ranking in the 3rd percentile compared to other EV players in its peer group.